Open AccessA phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma
Author(s) -
Elizabeth R. Gerstner,
Xiaobu Ye,
Dan G. Duda,
Michael A. Levine,
Tom Mikkelsen,
Thomas Kaley,
Jeffrey J. Olson,
Burt L. Nabors,
Manmeet S. Ahluwalia,
Patrick Y. Wen,
Rakesh K. Jain,
Tracy T. Batchelor,
Stuart A. Grossman
Publication year - 2015
Publication title -
neuro-oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.005
H-Index - 125
eISSN - 1523-5866
pISSN - 1522-8517
DOI - 10.1093/neuonc/nov085
Subject(s) - medicine , vascular endothelial growth factor , clinical endpoint , oncology , progression free survival , tumor progression , bevacizumab , tyrosine kinase inhibitor , phases of clinical research , gastroenterology , chemotherapy , clinical trial , cancer , vegf receptors
Despite being a highly vascularized tumor, glioblastoma response to anti-vascular endothelial growth factor (VEGF) therapy is transient, possibly because of tumor co-option of preexisting blood vessels and infiltration into surrounding brain. Integrins, which are upregulated after VEGF inhibition, may play a critical role in this resistance mechanism. We designed a study of cediranib, a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor, combined with cilengitide, an integrin inhibitor.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom